Jiangsu Recbio Technology Co., Ltd. (HKG:2179)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.710
-0.100 (-2.08%)
Jun 18, 2026, 10:14 AM HKT
Market Cap2.97B -28.6%
Revenue (ttm)14.16M
Net Income-679.25M
EPS-1.28
Shares Out 616.81M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,000
Open4.700
Previous Close4.810
Day's Range4.700 - 4.710
52-Week Range3.400 - 8.800
Beta0.08
Analystsn/a
Price Target14.13 (+200.0%)
Earnings DateMar 24, 2026

About Jiangsu Recbio Technology

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical trial; REC602, recombinant HPV bivalent vaccines targeting HPV type 6/11... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 491
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2179
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements